Wednesday 20th September 2017, 10:00am
Synpromics Ltd, the leader in gene control, today announces a new research partnership with Solid Biosciences, LLC. Under the terms of the agreement, Synpromics will provide Solid Biosciences access to a set of key muscle-selective promoter candidates to be used in the development of new treatment options for Duchenne muscular dystrophy (DMD).
The use of Synpromics’ synthetic promoters will enable the enhancement of Solid Biosciences’ investigational gene therapy candidates for the treatment of DMD.
These muscle-selective promoters have been designed using Synpromics’ PromPT® technology and bioinformatics expertise, and will be evaluated by Solid Biosciences for optimal product specific gene control.
“We are excited to leverage our PromPT® technology platform to generate promoter candidates closely matching the precise criteria and specific product requirements for Solid Biosciences’ muscle gene medicine programme in Duchenne.”
“The collaboration between the scientific teams will enable the effective and rapid in vivo evaluation of the candidate promoters as compared to industry standards.”
David Venables, CEO of Synpromics“The collaboration between the scientific teams will enable the effective and rapid in vivo evaluation of the candidate promoters as compared to industry standards.”
“Synpromics’ cutting-edge technology has the potential to enhance our gene therapy development efforts, helping us to fulfil our promise to bring meaningful therapies to all patients with this devastating disease.”
“This type of collaboration is key for building our next-generation gene therapy portfolio as we focus on enhancing fundamental aspects of our gene delivery and protein expression capabilities.”
Joel Schneider, PhD, Chief Technology Officer, Head of Exploratory R&D at Solid BiosciencesDuchenne muscular dystrophy (DMD) is a genetic muscle-wasting disease that is progressive, irreversible and ultimately fatal. DMD affects approximately one in every 3,500 to 5,000 live male births. Symptoms of DMD usually manifest between three to five years of age. As the disease progresses, patients are typically wheelchair-bound by their early teens and succumb to respiratory or heart failure in early adulthood.
There is no cure for DMD and, for the vast majority of patients, there are no satisfactory treatments.This research collaboration will help advance Solid’s programme to develop optimal product candidates for the company’s AAV muscle-directed gene therapy research programme.
This is the latest in a series of exciting deals signed by Synpromics, contributing to the rapid growth of the company and necessitating their move into new world-class facilities at the Roslin Innovation Centre, announced last week.
For further information, please contact:
Corporate Contact:
Dr. David Venables, CEO
Synpromics Ltd
T: +44 (0)7825 323439
E: David.Venables@synpromics.com
PR Contact:
Deborah Cockerill / Emma Pickup
Sciad Communications Ltd
T: +44 (0)20 7470 8801
E: synpromics@sciad.com
Roslin Innovation Centre
The University of Edinburgh
Easter Bush Campus
Midlothian EH25 9RG
